Future perspectives in pulmonary arterial hypertension

doi:10.1183/16000617.0084-2016

Review

. 2016 Dec;25(142):381-389.

doi: 10.1183/16000617.0084-2016.

Future perspectives in pulmonary arterial hypertension

Gérald Simonneau^{1

2

3}, Marius M Hoeper⁴, Vallerie McLaughlin⁵, Lewis Rubin⁶, Nazzareno Galiè⁷

Affiliations

¹ Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France gerald.simonneau@bct.aphp.fr.
² AP-HP, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
³ INSERM U-999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
⁴ Dept of Respiratory Medicine, Hannover Medical School and German Centre for Lung Research, Hannover, Germany.
⁵ Dept of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
⁶ Dept of Medicine, University of California, San Diego, CA, USA.
⁷ Dept of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.

PMID: 27903660
PMCID: PMC9487553
DOI: 10.1183/16000617.0084-2016

Review

Future perspectives in pulmonary arterial hypertension

Gérald Simonneau et al. Eur Respir Rev. 2016 Dec.

. 2016 Dec;25(142):381-389.

doi: 10.1183/16000617.0084-2016.

Authors

Gérald Simonneau^{1

2

3}, Marius M Hoeper⁴, Vallerie McLaughlin⁵, Lewis Rubin⁶, Nazzareno Galiè⁷

Affiliations

¹ Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France gerald.simonneau@bct.aphp.fr.
² AP-HP, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
³ INSERM U-999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
⁴ Dept of Respiratory Medicine, Hannover Medical School and German Centre for Lung Research, Hannover, Germany.
⁵ Dept of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.
⁶ Dept of Medicine, University of California, San Diego, CA, USA.
⁷ Dept of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.

PMID: 27903660
PMCID: PMC9487553
DOI: 10.1183/16000617.0084-2016

Abstract

While there have been advances in the field of pulmonary arterial hypertension (PAH), disease management remains suboptimal for many patients. The development of novel treatments and strategies can provide opportunities to target other mechanisms that play a role in the complex pathobiology of PAH outside of the three main pathophysiological pathways. In this review, we highlight some of the potential PAH therapies or techniques that are being, or have been, investigated in phase II clinical trials. This review also discusses potential points for consideration in the development of novel therapies that target putative disease mediators or modifiers.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside this article at err.ersjournals.com

Cited by

Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.
Chan SY, Rubin LJ. Chan SY, et al. Eur Respir Rev. 2017 Dec 20;26(146):170094. doi: 10.1183/16000617.0094-2017. Print 2017 Dec 31. Eur Respir Rev. 2017. PMID: 29263174 Free PMC article. Review.
Pulmonary arterial hypertension: tailoring treatment to risk in the current era.
Gaine S, McLaughlin V. Gaine S, et al. Eur Respir Rev. 2017 Dec 20;26(146):170095. doi: 10.1183/16000617.0095-2017. Print 2017 Dec 31. Eur Respir Rev. 2017. PMID: 29263175 Free PMC article. Review.
Putting skin in the game: dermis-derived stem cells provide insight into familial pulmonary hypertension.
Maloney JP. Maloney JP. Stem Cell Investig. 2017 May 5;4:35. doi: 10.21037/sci.2017.04.05. eCollection 2017. Stem Cell Investig. 2017. PMID: 28607909 Free PMC article. No abstract available.
RELMα Licenses Macrophages for Damage-Associated Molecular Pattern Activation to Instigate Pulmonary Vascular Remodeling.
Lin Q, Fan C, Skinner JT, Hunter EN, Macdonald AA, Illei PB, Yamaji-Kegan K, Johns RA. Lin Q, et al. J Immunol. 2019 Dec 1;203(11):2862-2871. doi: 10.4049/jimmunol.1900535. Epub 2019 Oct 14. J Immunol. 2019. PMID: 31611261 Free PMC article.
Identifying Key Biomarkers in Pediatric Pulmonary Hypertension: An Investigative Approach.
Mindubayeva F, Akhmaltdinova L, Ospanova M, Tukbekova B, Bolatbekuly Z, Niyazova Y, Salikhova Y, Avdienko O, Akhmetova M. Mindubayeva F, et al. Children (Basel). 2024 Jun 17;11(6):737. doi: 10.3390/children11060737. Children (Basel). 2024. PMID: 38929316 Free PMC article.

See all "Cited by" articles

References

1. Humbert M, Lau EM, Montani D, et al. . Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014; 130: 2189–2208. - PubMed
1. Galiè N, Barbera JA, Frost AE, et al. . Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834–844. - PubMed
1. Pulido T, Adzerikho I, Channick R, et al. . Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818. - PubMed
1. Sitbon O, Channick R, Chin KM, et al. . Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–2533. - PubMed
1. Humbert M, Simonneau G, Rubin LJ. A decade of achievement in pulmonary hypertension. Eur Respir Rev 2011; 20: 215–217. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Humbert M, Lau EM, Montani D, et al. . Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014; 130: 2189–2208. - PubMed

[2] Humbert M, Lau EM, Montani D, et al. . Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014; 130: 2189–2208. - PubMed

[3] Galiè N, Barbera JA, Frost AE, et al. . Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834–844. - PubMed

[4] Galiè N, Barbera JA, Frost AE, et al. . Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834–844. - PubMed

[5] Pulido T, Adzerikho I, Channick R, et al. . Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818. - PubMed

[6] Pulido T, Adzerikho I, Channick R, et al. . Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818. - PubMed

[7] Sitbon O, Channick R, Chin KM, et al. . Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–2533. - PubMed

[8] Sitbon O, Channick R, Chin KM, et al. . Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–2533. - PubMed

[9] Humbert M, Simonneau G, Rubin LJ. A decade of achievement in pulmonary hypertension. Eur Respir Rev 2011; 20: 215–217. - PMC - PubMed

[10] Humbert M, Simonneau G, Rubin LJ. A decade of achievement in pulmonary hypertension. Eur Respir Rev 2011; 20: 215–217. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Future perspectives in pulmonary arterial hypertension

Affiliations

Future perspectives in pulmonary arterial hypertension

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical